Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations.
anti-infective agents
antifungal therapy
fungal infections
isavuconazole
therapeutic drug monitoring
Journal
Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827
Informations de publication
Date de publication:
22 Jun 2020
22 Jun 2020
Historique:
received:
13
05
2020
revised:
17
06
2020
accepted:
19
06
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
Isavuconazole (ISA) is a triazole antifungal agent recommended for treatment of invasive aspergillosis or mucormycosis. The objective of this study was to evaluate ISA levels in a real world setting in a mixed patient cohort including patients with non-malignant diseases and extracorporeal treatments, and to correlate findings with efficacy and safety outcomes. We investigated 33 ISA treatment courses in 32 adult patients with hematological and other underlying diseases and assessed the clinical response, side effects and ISA trough plasma concentrations. ISA treatment led to complete and partial response in 87% of patients and was well tolerated. The median ISA plasma concentration was 3.05 µg/mL (range 1.38-9.1, IQR 1.93-4.35) in patients without renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO) and significantly lower in patients with RRT including cases with additional ECMO or Cytosorb
Identifiants
pubmed: 32580296
pii: jof6020090
doi: 10.3390/jof6020090
pmc: PMC7344482
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Pfizer
ID : WI242120_IIR
Références
Am J Respir Crit Care Med. 2012 Jul 1;186(1):56-64
pubmed: 22517788
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29735569
Med Mycol. 2019 Apr 1;57(Supplement_2):S168-S178
pubmed: 30816967
J Antimicrob Chemother. 2009 Apr;63(4):767-70
pubmed: 19218271
Haematologica. 2017 Mar;102(3):433-444
pubmed: 28011902
Clin Infect Dis. 2016 Aug 15;63(4):e1-e60
pubmed: 27365388
Clin Infect Dis. 2008 Sep 1;47(5):674-83
pubmed: 18637757
Ther Drug Monit. 2019 Oct;41(5):657-664
pubmed: 31568234
J Antimicrob Chemother. 2012 Aug;67(8):2029-33
pubmed: 22566591
Lancet. 2016 Feb 20;387(10020):726-8
pubmed: 26684608
Lancet Respir Med. 2018 Oct;6(10):782-792
pubmed: 30076119
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4568-76
pubmed: 27185799
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31427296
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
J Antimicrob Chemother. 2019 Mar 1;74(3):761-767
pubmed: 30476108
Drug Des Devel Ther. 2018 Apr 30;12:1033-1044
pubmed: 29750016
Antimicrob Agents Chemother. 2018 May 25;62(6):
pubmed: 29581116
J Antimicrob Chemother. 2019 Aug 1;74(8):2341-2346
pubmed: 31119272
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28923872
Antimicrob Agents Chemother. 2019 Sep 23;63(10):
pubmed: 31405852
J Extra Corpor Technol. 2017 Sep;49(3):150-159
pubmed: 28979038
Mycoses. 2019 Sep;62(9):716-729
pubmed: 31254420
Lancet Infect Dis. 2016 Jul;16(7):828-837
pubmed: 26969258
Lancet. 2016 Feb 20;387(10020):760-9
pubmed: 26684607